Vis børsmeldingen
committed private placement (the “Private Placement”), and the intention to
carry out a subsequent repair offering (the “Subsequent Offering”) of up to
3,846,153 new shares at a subscription price per new share of NOK 2.60, directed
towards shareholders of Ultimovacs or Zelluna as of close of trading on 17
December 2024 who (i) were not allocated shares in the Private Placement; (ii)
were not offered to provide pre-commitments for the Private Placement; and (iii)
are not resident in a jurisdiction where such offering would be unlawful or
would (in jurisdictions other than Norway) require any prospectus, filing,
registration or similar action.
The following key information is provided with respect to the potential repair
offering to be carried out by Ultimovacs.
Date on which the terms and conditions of the repair offering were announced:
17 December 2024
Last day including right: 17 December 2024
Ex-date: 18 December 2024
Record date: 19 December 2024
Date of approval: Expected on or about 9 January 2024 (general meeting
authorisation)
Maximum number of new shares: 3,846,153
Subscription price: NOK 2.60
Other information: Any Subsequent Offering is subject to the prior publication
of a prospectus in accordance with applicable legislation. Notwithstanding the
foregoing, the Company’s Board of Directors may, in its sole discretion, decide
that the Company shall not carry out the Subsequent Offering, for example if the
prevailing market price of the Company’s shares trade lower than the
subscription price and if the number of shares traded at or below the
subscription price is greater than the number of offer shares in the Subsequent
Offering, thereby making a subsequent offering redundant.
This information is published in accordance with the requirements of the
Continuing Obligations.
Kilde
